Research Alert: CFRA Keeps Hold Opinion On Shares Of Eastman Chemical Company
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target price by $7 to $78, valuing EMN shares at 12.2x our 2026 EPS estimate of $6.35 (raised from $6.09) and at 11x our 2027 EPS estimate of $7.10. Our target multiples compare to EMN's three-year average forward multiple of 11x. EMN posted Q1 adjusted EPS of $1.09, down from $1.91 a year ago, missing our $1.37 estimate but beating the $1.06 consensus. Sales fell 5% to $2.177B amid customer inventory destocking, weak consumer discretionary demand, and Middle East conflict impacts. The company implemented ~$500M in price increases to offset raw material inflation, while the Kingsport methanolysis facility remained on track to deliver ~$30M in incremental full-year earnings. Management maintained its cost-reduction target of $125M-$150M in savings net of inflation for 2026. Adjusted EBIT margin contracted 440 bps to 9.2% as lower volumes and challenging market conditions compressed profitability across most segments.
